SCYNEXIS, Inc. (SCYX) Stock Price

SCYXStock

$3.67−42.66%52W

Market Cap$36.52M

P/E—

PEG Ratio—

Div yield—

Beta1.22

SCYX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-64.93%

Price vs S&P 500 (4W)-15.27%

VGM Score64.21

Book Value / Share (Quarterly)$6.73

P/TBV (Annual)1.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)59.36%

Cash Flow / Share (Quarterly)$-1.34

Price vs S&P 500 (YTD)-39.40%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)57.58%

EPS (TTM)$-2.16

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-2.16

Revenue Growth (5Y)99.01%

EPS (Annual)$-1.38

ROI (Annual)-17.44%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-409.20%

Cash / Share (Quarterly)$5.44

Revenue Growth QoQ (YoY)-82.77%

ROA (Last FY)-14.58%

Revenue Growth TTM (YoY)489.78%

EBITD / Share (TTM)$-2.94

ROE (5Y Avg)-401.32%

Operating Margin (TTM)-29.45%

Cash Flow / Share (Annual)$-0.97

P/B Ratio0.55x

P/B Ratio (Quarterly)0.60x

Net Income / Employee (Annual)$-478,300

EV / Revenue (TTM)1.35x

Net Interest Coverage (TTM)31.96x

ROA (TTM)-15.58%

EV / EBITDA (TTM)0.35x

EPS Incl Extra (Annual)$-1.38

Current Ratio (Annual)7.04x

Quick Ratio (Quarterly)9.55x

3-Month Avg Trading Volume0.23M

52-Week Price Return-42.66%

Revenue / Employee (TTM)$1,067,500

Tangible BV / Share (Quarterly)$1.96

P/S Ratio (Annual)1.77x

Asset Turnover (Annual)0.35x

52-Week High$9.12

Operating Margin (5Y Avg)-636.97%

EPS Excl Extra (Annual)$-1.38

Tangible BV CAGR (5Y)-33.31%

26-Week Price Return-55.02%

Quick Ratio (Annual)7.00x

13-Week Price Return-14.05%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.65x

Enterprise Value$26.03M

Revenue / Share Growth (5Y)29.25%

Asset Turnover (TTM)0.31x

Book Value / Share Growth (5Y)51.09%

Revenue / Employee (Annual)$1,144,500

Inventory Turnover (Annual)0.92x

Pretax Margin (Annual)-41.79%

Cash / Share (Annual)$7.36

3-Month Return Std Dev91.30%

Gross Margin (5Y Avg)75.47%

Net Income / Employee (TTM)$-568,600

ROE (Last FY)-17.44%

Net Interest Coverage (Annual)8.40x

EPS Basic Excl Extra (Annual)$-1.38

P/FCF (TTM)1.98x

Receivables Turnover (TTM)133.52x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.16

Receivables Turnover (Annual)133.47x

ROI (TTM)-21.10%

P/S Ratio (TTM)1.90x

Pretax Margin (5Y Avg)-431.52%

Revenue / Share (Annual)$3.30

Tangible BV / Share (Annual)$15.69

Price vs S&P 500 (52W)-58.19%

Year-to-Date Return-27.47%

5-Day Price Return-8.93%

EPS Normalized (Annual)$-1.38

ROA (5Y Avg)-16.97%

Net Profit Margin (Annual)-41.79%

Month-to-Date Return-25.71%

EBITD / Share (Annual)$-2.58

Operating Margin (Annual)-78.03%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-27.82%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.16

P/TBV (Quarterly)1.14x

P/B Ratio (Annual)0.54x

Inventory Turnover (TTM)34.63x

Pretax Margin (TTM)57.58%

Book Value / Share (Annual)$9.07

Price vs S&P 500 (13W)-16.74%

Beta1.22x

P/FCF (Annual)0.61x

Revenue / Share (TTM)$1.63

ROE (TTM)-21.10%

52-Week Low$3.53

vGradeA

gGradeB

mGradeC

vgmGradeB

SCYX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.51	$0.63	+224.34%(+$1.14)
Q1 2026	May 11, 2026	-$0.99	-$3.36	-240.54%(-$2.37)
Q4 2025	Mar 4, 2026	$1.01	$2.00	+97.37%(+$0.99)
Q3 2025	Nov 5, 2025	-$1.60	-$1.36	+15.00%(+$0.24)
Q2 2025	Aug 13, 2025	-$1.52	-$1.12	+26.32%(+$0.40)

SCYX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.22

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SCYXSCYNEXIS, Inc.	A	B	C	1.9x	489.8%	100.0%	—	$3.67
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About SCYNEXIS, Inc.

SCYNEXIS develops novel antifungal therapies to treat serious fungal infections with significant unmet medical needs. The company's lead candidate, ibrexafungerp, is an oral and intravenous glucan synthase inhibitor demonstrating broad-spectrum activity against drug-resistant Candida and Aspergillus species. The medication's differentiated mechanism of action offers potential advantages over existing antifungal treatments for invasive fungal infections.